Burden of norovirus in healthcare facilities and strategies for outbreak control

Journal of Hospital Infection

Volumn 89, Issue 4, 2015, Pages 296-301

  Kambhampati, A ^a   Koopmans, M ^b,c   Lopman, B A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiviral agents; Gastroenteritis; Genogroup II type 4; Infection control; Norovirus

Indexed keywords

ANTIGEN; FAVIPIRAVIR; HISTO BLOOD GROUP ANTIGEN; NEUTRALIZING ANTIBODY; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ACUTE GASTROENTERITIS; CANCER PATIENT; CAUSE OF DEATH; COMORBIDITY; DISEASE TRANSMISSION; DISINFECTION; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; HAND WASHING; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH SERVICE; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; INFECTION CONTROL; LONG TERM CARE; MORTALITY; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PATIENT TRANSPORT; PHASE 3 CLINICAL TRIAL (TOPIC); PROTECTIVE EQUIPMENT; REHYDRATION; RESIDENTIAL CARE; SHORT SURVEY; TERTIARY CARE CENTER; VACCINATION; VIRUS ENTRY; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS STRAIN; CALICIVIRIDAE INFECTIONS; CLASSIFICATION; CROSS INFECTION; EPIDEMIC; GASTROENTERITIS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; PROCEDURES; VIROLOGY;

CALICIVIRIDAE INFECTIONS; CROSS INFECTION; DISEASE OUTBREAKS; GASTROENTERITIS; GENOTYPE; HEALTH FACILITIES; HUMANS; INFECTION CONTROL; NOROVIRUS;

EID: 84933182882     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2015.01.011     Document Type: Short Survey

References (79)

1. Ahmed S.M., Hall A.J., Robinson A.E., et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis 2014, 14:725-730.
2. Hall A.J., Lopman B.A., Payne D.C., et al. Norovirus disease in the United States. Emerg Infect Dis 2013, 19:1198-1205.
3. Lopman B.A., Reacher M.H., Vipond I.B., et al. Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002-2003. Emerg Infect Dis 2004, 10:1827-1834.
4. Lopman B.A., Adak G.K., Reacher M.H., Brown D.W. Two epidemiologic patterns of norovirus outbreaks: surveillance in England and Wales, 1992-2000. Emerg Infect Dis 2003, 9:71.
5. Kroneman A., Verhoef L., Harris J., et al. Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006. JClin Microbiol 2008, 46:2959-2965.
6. Lopman B., Vennema H., Kohli E., et al. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet 2004, 363(9410):682-688.
7. Godoy P., Ferrus G., Torner N., et al. High incidence of norovirus GII.4 outbreaks in hospitals and nursing homes in Catalonia (Spain), 2010-2011. Epidemiol Infect 2014, 10.1017/S0950268814001204.
8. Hall A.J., Wikswo M.E., Manikonda K., Roberts V.A., Yoder J.S., Gould L.H. Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. Emerg Infect Dis 2013, 19(8).
9. Rhinehart E., Walker S., Murphy D., O'Reilly K., Leeman P. Frequency of outbreak investigations in US hospitals: results of a national survey of infection preventionists. Am J Infect Control 2012, 40:2-8.
10. Tam C.C., Rodrigues L.C., Viviani L., et al. Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut 2012, 61:69-77.
11. Beersma M.F., Sukhrie F.H., Bogerman J., et al. Unrecognized norovirus infections in health care institutions and their clinical impact. JClin Microbiol 2012, 50:3040-3045.
12. Patel M.M., Hall A.J., Vinjé J., Parashar U.D. Noroviruses: a comprehensive review. JClin Virol 2009, 44:1-8.
13. Kroneman A., Vega E., Vennema H., et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013, 158:2059-2068.
14. Teunis P.F., Moe C.L., Liu P., et al. Norwalk virus: how infectious is it?. JMed Virol 2008, 80:1468-1476.
15. Atmar J., Mullen E. Norovirus in immunocompromised patients. Oncol Nurs Forum 2013, 40:434-436.
16. Repp K.K., Keene W.E. Apoint-source norovirus outbreak caused by exposure to fomites. JInfect Dis 2012, 205:1639-1641.
17. Hall A.J., Wikswo M.E., Pringle K., et al. Vital signs: foodborne norovirus outbreaks - United States, 2009-2012. Morb Mortal Wkly Rep 2014, 63:491-495.
18. Arvelo W., Sosa S.M., Juliao P., et al. Norovirus outbreak of probable waterborne transmission with high attack rate in a Guatemalan resort. JClin Virol 2012, 55:8-11.
19. Cheesbrough J.S., Green J., Gallimore C.I., Wright P.A., Brown D.W. Widespread environmental contamination with Norwalk-like viruses (NLV) detected in a prolonged hotel outbreak of gastroenteritis. Epidemiol Infect 2000, 125:93-98.
20. Glass R.I., Parashar U.D., Estes M.K. Norovirus gastroenteritis. NEngl J Med 2009, 361:1776-1785.
21. Morter S., Bennet G., Fish J., et al. Norovirus in the hospital setting: virus introduction and spread within the hospital environment. JHosp Infect 2011, 77:106-112.
22. Thornley C.N., Emslie N.A., Sprott T.W., Greening G.E., Rapana J.P. Recurring norovirus transmission on an airplane. Clin Infect Dis 2011, 53:521-526.
23. Nenonen N.P., Hannoun C., Svensson L., et al. Norovirus GII.4 detection in environmental samples from patient rooms during nosocomial outbreaks. JClin Microbiol 2014, 52:2352-2358.
24. Phillips G., Tam C.C., Rodrigues L.C., Lopman B. Prevalence and characteristics of asymptomatic norovirus infection in the community in England. Epidemiol Infect 2010, 138:1454-1458.
25. Atmar R.L., Opekun A.R., Gilger M.A., et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis 2008, 14:1553.
26. García C., DuPont H.L., Long K.Z., Santos J.I., Ko G. Asymptomatic norovirus infection in Mexican children. JClin Microbiol 2006, 44:2997-3000.
27. Lopman B.A., Reacher M.H., Vipond I.B., Sarangi J., Brown D.W. Clinical manifestation of norovirus gastroenteritis in health care settings. Clin Infect Dis 2004, 39:318-324.
28. Frange P., Touzot F., Debré M., et al. Prevalence and clinical impact of norovirus fecal shedding in children with inherited immune deficiencies. JInfect Dis 2012, 206:1269-1274.
29. Kaufman S.S., Green K.Y., Korba B.E. Treatment of norovirus infections: moving antivirals from the bench to the bedside. Antiviral Res 2014, 105:80-91.
30. Munir N., Liu P., Gastañaduy P., Montes J., Shane A., Moe C. Norovirus infection in immunocompromised children and children with hospital-acquired acute gastroenteritis. JMed Virol 2014, 86:1203-1209.
31. Wingfield T., Gallimore C.I., Xerry J., et al. Chronic norovirus infection in an HIV-positive patient with persistent diarrhoea: a novel cause. JClin Virol 2010, 49:219-222.
32. Hall A.J., Jan Vinjé D.V.M., Lopman B., et al. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep 2011, 60(RR-3):1-18.
33. Sukhrie F.H., Siebenga J.J., Beersma M.F., Koopmans M. Chronic shedders as reservoir for nosocomial transmission of norovirus. JClin Microbiol 2010, 48:4303-4305.
34. Siebenga J.J., Beersma M.F., Vennema H., van Biezen P., Hartwig N.J., Koopmans M. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for invivo molecular evolution. JInfect Dis 2008, 198:994-1001.
35. Ludwig A., Adams O., Laws H.J., Schroten H., Tenenbaum T. Quantitative detection of norovirus excretion in pediatric patients with cancer and prolonged gastroenteritis and shedding of norovirus. JMed Virol 2008, 80:1461-1467.
36. Harris J.P., Edmunds W.J., Pebody R., Brown D.W., Lopman B.A. Deaths from norovirus among the elderly, England and Wales. Emerg Infect Dis 2008, 14:1546-1552.
37. Hall A.J., Curns A.T., McDonald L.C., Parashar U.D., Lopman B.A. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012, 55:216-223.
38. Gustavsson L., Andersson L.M., Lindh M., Westin J. Excess mortality following community-onset norovirus enteritis in the elderly. JHosp Infect 2011, 79:27-31.
39. Koo H.L., DuPont H.L. Noroviruses as a potential cause of protracted and lethal disease in immunocompromised patients. Clin Infect Dis 2009, 49:1069-1071.
40. Desai R., Hembree C.D., Handel A., et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin Infect Dis 2012, 55:189-193.
41. van Asten L., Siebenga J., van den Wijngaard C., et al. Unspecified gastroenteritis illness and deaths in the elderly associated with norovirus epidemics. Epidemiology 2011, 22:336-343.
42. van Asten L., van den Wijngaard C., van Pelt W., et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. JInfect Dis 2012, 206:628-639.
43. Lindesmith L.C., Donaldson E.F., Lobue A.D., et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008, 5:e31.
44. Siebenga J.J., Vennema H., Zheng D.P., et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. JInfect Dis 2009, 200:802-812.
45. Debbink K., Lindesmith L.C., Donaldson E.F., et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. JInfect Dis 2013, 208:1877-1887.
46. Sakon N., Yamazaki K., Nakata K., et al. Impact of genotype-specific herd immunity on the circulatory dynamism of norovirus: a 10-year longitudinal study of viral acute gastroenteritis. JInfect Dis 2014, 10.1093/infdis/jiu496.
47. Siebenga J.J., Vennema H., Renckens B., et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. JVirol 2007, 81:9932-9941.
48. Bull R.A., Tu E.T., McIver C.J., Rawlinson W.D., White P.A. Emergence of a new norovirus genotype II.4 variant associated with global outbreaks of gastroenteritis. JClin Microbiol 2006, 44:327-333.
49. White P.A. Evolution of norovirus. Clin Microbiol Infect 2014, 20:741-745.
50. Trivedi T.K., DeSalvo T., Lee L., et al. Hospitalizations and mortality associated with norovirus outbreaks in nursing homes, 2009-2010. JAMA 2012, 308:1668-1675.
51. Rondy M., Koopmans M., Rotsaert C., et al. Norovirus disease associated with excess mortality and use of statins: a retrospective cohort study of an outbreak following a pilgrimage to Lourdes. Epidemiol Infect 2011, 139:453-463.
52. Harris J.P., Lopman B.A., Cooper B.S., O'Brien S.J. Does spatial proximity drive norovirus transmission during outbreaks in hospitals?. BMJ Open 2013, 3(7).
53. Johnston C.P., Qiu H., Ticehurst J.R., et al. Outbreak management and implications of a nosocomial norovirus outbreak. Clin Infect Dis 2007, 45:534-540.
54. Sukhrie F.H., Teunis P., Vennema H., et al. Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis 2012, 54:931-937.
55. Harris J., Lopman B., O'Brien S. Infection control measures for norovirus: a systematic review of outbreaks in semi-enclosed settings. JHosp Infect 2010, 74:1-9.
56. Barclay L., Park G.W., Vega E., et al. Infection control for norovirus. Clin Microbiol Infect 2014, 20:731-740.
57. MacCannell T., Umscheid C.A., Agarwal R.K., Lee I., Kuntz G., Stevenson K.B. Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Infect Control Hosp Epidemiol 2011, 32:939-969. Healthcare Infection Control Practices Advisory Committee - HICPAC.
58. Friesema I.H., Vennema H., Heijne J.C., et al. Norovirus outbreaks in nursing homes: the evaluation of infection control measures. Epidemiol Infect 2009, 137:1722-1733.
59. Zingg W., Colombo C., Jucker T., Bossart W., Ruef C. Impact of an outbreak of norovirus infection on hospital resources. Infect Control Hosp Epidemiol 2005, 26:263-267.
60. Arias A., Emmott E., Vashist S., Goodfellow I. Progress towards the prevention and treatment of norovirus infections. Future Microbiol 2013, 8:1475-1487.
61. Bartsch S.M., Lopman B.A., Hall A.J., Parashar U.D., Lee B.Y. The potential economic value of a human norovirus vaccine for the United States. Vaccine 2012, 30:7097-7104.
62. Vesikari T., Blazevic V. Norovirus vaccine: one step closer. JInfect Dis 2014, 10.1093/infdis/jiu498.
63. Jones M.K., Watanabe M., Zhu S., et al. Enteric bacteria promote human and murine norovirus infection of B cells. Science 2014, 346:755-759.
64. Richardson C., Bargatze R.F., Goodwin R., Mendelman P.M. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev Vaccines 2013, 12:155-167.
65. Atmar R.L., Estes M.K. Norovirus vaccine development: next steps. Expert Rev Vaccines 2012, 11:1023-1025.
66. Debbink K., Lindesmith L.C., Baric R.S. The state of norovirus vaccines. Clin Infect Dis 2014, 58:1746-1752.
67. Roldão A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Exp Rev Vaccines 2010, 9:1149-1176.
68. Atmar R.L., Bernstein D.I., Harro C.D., et al. Norovirus vaccine against experimental human Norwalk virus illness. NEngl J Med 2011, 365:2178-2187.
69. Bernstein D.I., Atmar R.L., Lyon G.M., et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. JInfect Dis 2014, 10.1093/infdis/jiu497.
70. Treanor J.J., Atmar R.L., Frey S.E., et al. Anovel intramuscular bivalent norovirus virus-like particle vaccine candidate - reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. JInfect Dis 2014, 210:1763-1771.
71. Velasquez L.S., Shira S., Berta A.N., et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 2011, 29:5221-5231.
72. Tamminen K., Lappalainen S., Huhti L., Vesikari T., Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013, 8:e70409.
73. Tan M., Jiang X. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond) 2012, 7:889-897.
74. Fang H., Tan M., Xia M., Wang L., Jiang X. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PloS One 2013, 8:e63269.
75. Kocher J., Bui T., Giri-Rachman E., et al. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs. JVirol 2014, 88:9728-9743.
76. Ramani S., Atmar R.L., Estes M.K. Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol 2014, 30:25-33.
77. Parrino T.A., Schreiber D.S., Trier J.S., Kapikian A.Z., Blacklow N.R. Clinical immunity in acute gastroenteritis caused by Norwalk agent. NEngl J Med 1977, 297:86-89.
78. Johnson P.C., Mathewson J.J., DuPont H.L., Greenberg H.B. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. JInfect Dis 1990, 161:18-21.
79. Wyatt R.G., Dolin R., Blacklow N.R., et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. JInfect Dis 1974, 129:709-714.